Overview

Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate if colesevelam add-on to pioglitazone therapy for type 2 diabetes mellitus will be safe, well tolerated, and efficacious.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Colesevelam Hydrochloride
Pioglitazone